Entelos,
Inc., a simulation and modeling company focused on human
health, announced today that the U.S. Patent and Trademark Office has
granted U.S. Patent No. 7,654,955 entitled “Apparatus and Methods for
Assessing Metabolic Substrate Utilization” to the Company. These methods
further strengthen the Entelos® Metabolism PhysioLab®
platform and leverage insights about human physiology that can lead to
improved diagnosis, clinical testing, and personalized treatment across
a highly variable patient population. This method may also be used to
improve the selection of patients for clinical trials of metabolic
therapies and diagnostics.
“Our biosimulation platforms and
insightful ‘what if’ scenarios have already led to better decisions in
R&D and this new diagnostic capability can stratify patients based on
underlying differences in their disease state to optimize care.”
“We are pleased to add this new patent to cap our leadership position in
metabolic disorders such as diabetes and obesity,” stated Jeff
Trimmer, CSO of Entelos. “Our biosimulation platforms and
insightful ‘what if’ scenarios have already led to better decisions in
R&D and this new diagnostic capability can stratify patients based on
underlying differences in their disease state to optimize care.”